CAMBRIDGE, Mass., Sept. 26, 2016 -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference, being held in New York City on September 27, 2016.
| Ladenburg Thalmann 2016 Healthcare Conference | |
| Date: | Tuesday, September 27 |
| Time: | 11:30am Eastern Time |
| Location: | Sofitel Hotel New York, Odeon Room |
| Webcast: | http://wsw.com/webcast/ladenburg2/clcd |
About CoLucid Pharmaceuticals, Inc.
CoLucid was founded in 2005 and is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
CONTACT Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (857) 285-6494 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 



